Landmark step in HIV prevention
The WHO has approved Lenacapavir, a long-acting injectable that protects against HIV for 6 months with just two injections per year.
Originally priced at $28,000 per person annually, a new global deal will slash the cost to $40, making it accessible in over 120 low- and middle-income countries by 2027.
This breakthrough could transform prevention for:
- Young people
- Women & girls
- LGBT+ communities
- Sex workers
- People who use drugs
As Prof. Saiqa Mullick (Wits RHI) said: “The real work begins now, building demand, securing commitments, and preparing systems so countries are ready for rapid introduction and scale.”
For Southeast Asia, where stigma, criminalization, and health gaps persist, equitable access and community readiness will be essential.
Read more via BBC: https://www.bbc.co.uk/news/articles/cgmzn8802d7o
#HarmReduction #HIVPrevention #Lenacapavir #GatesFoundation #CHAI #AHRA #BBC
